CANDOR Study Gives Hope for Relapsed and Refractory Myeloma at Hackensack University Medical Center

Phase III Trial Confirms Carfilzomib and Dexamethasone as Emerging Standard of Care

Researchers at Hackensack University Medical Center contributed to updated analysis of the global CANDOR study. Their findings, published in The Lancet Oncology, could change the standard of care for multiple myeloma.

• The Phase III CANDOR trial addresses the unmet need for treating patients with relapsed or refractory multiple myeloma, especially in those previously exposed or refractory to lenalidomide.
• Updated efficacy and safety analysis from the Phase III CANDOR study compared carfilzomib, dexamethasone and daratumumab (KdD) with carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma.
• The study confirmed a clear, maintained progression-free survival benefit of KdD over Kd. Longer follow-up was confirmed, defining KdD as an emerging standard of care for patients with relapsed or refractory multiple myeloma.

In this updated analysis of the randomized, multi-center, open-label, Phase III CANDOR study, adult patients with relapsed or refractory multiple myeloma, at least a partial response to between one and three previous therapies, and Eastern Cooperative Oncology Group performance status of 0-2, were recruited from 102 medical centers globally. Participants were stratified by disease stage, previous proteasome inhibitor or anti-CD38 antibody exposure and number of previous therapies.

Learn more about innovative cancer treatments at Hackensack University Medical Center.